Table 2.
Exposure to laxative, antiparkinsonian, antidepressant and β‐adrenergic during period evaluated in 79 patients
| Data | Number of patients | Median time interval (interquartile range) years | Person‐years |
|---|---|---|---|
| Maintenance laxative(s): | 60 | 3.2 (1.1, 5.1) | 209 |
| bulk‐forming | 59 | 2.9 (1.0, 5.0) | 199 |
| osmotic | 56 | 2.8 (1.1, 4.4) | 176 |
| enterokinetic | 25 | 1.9 (0.7, 2.6) | 43 |
| Antiparkinsonian agent(s): | |||
| dopaminergic agonists | 48 | 3.3 (2.1, 6.8) | 206 |
| monoamine oxidase‐B inhibitor | 48 | 3.4 (1.1, 6.5) | 195 |
| anticholinergic | 31 | 4.5 (2.4, 7.6) | 151 |
| levodopa combination | 31 | 3.5 (2.3, 6.6) | 127 |
| amantadine | 24 | 3.0 (1.8, 6.9) | 95 |
| Antidepressant | 13 | 3.6 (0.7, 9.7) | 66 |
| Β‐adrenergic receptor antagonist | 11 | 4.0 (0.6, 4.6) | 38 |